The 2 mg Wegovy Question — and Why the Answer Matters

The misconception: why people search for a "2 mg" strength

A question our prescribers hear most weeks is some version of: "I've read about the 2 mg dose, is that what I should be on?" It comes up so often because the number 2 appears prominently in Wegovy conversations. The 2.4 mg maintenance dose gets rounded down in casual writing, on social media, and occasionally even in journalism. The result is that "2 mg Wegovy" circulates as if it were an official strength.

It isn't. Wegovy's licensed UK doses are 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, as set out in the medicine's Summary of Product Characteristics on the eMC. The 2.4 mg pen is the standard maintenance target, the dose most adults reach after approximately 16 weeks of gradual titration. Nothing sits between 1.7 mg and 2.4 mg. There is no 2 mg rung.

This matters beyond pedantry. If someone sources what they believe to be a "2 mg" product from an unverified seller, they may be buying a counterfeit. The MHRA has flagged fake weight-loss pens repeatedly, and incorrect dose markings are one of the warning signs. Knowing the real schedule is a safety check as much as a factual one. If you have come across references to Wegovy 2.5 mg, that page explains why that strength does not exist in the UK licensed schedule either. You can find full detail on every Wegovy dose if you want to see the complete picture.

What 2.4 mg actually does, and why titration exists

Semaglutide works by mimicking GLP-1, a gut hormone that signals fullness to the brain, slows gastric emptying and helps regulate appetite. At 2.4 mg (the dose people probably mean when they write "2 mg Wegovy") the effect on appetite is at its most pronounced within the licensed schedule.

The titration process is deliberate. Starting at 0.25 mg keeps gastrointestinal side effects manageable while the body adjusts. Nausea, queasiness and changes in bowel habit are common early on, particularly after each dose step. Moving slowly through 0.5 mg, then 1 mg, then 1.7 mg reduces the intensity of those effects. By the time a patient reaches the 2.4 mg maintenance stage, most have settled into the medicine reasonably well.

STEP 1, the pivotal semaglutide trial published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg dose. That figure comes from a structured trial population alongside lifestyle support, individual outcomes vary, and no result is guaranteed. The maximum weight loss people see on Wegovy depends on many factors beyond the dose alone.

One further point worth knowing: from January 2026 a 7.2 mg dose received MHRA approval, including a dedicated single-dose pen confirmed in April 2026. It is not a replacement for 2.4 mg but an option for patients who have already reached that level and may benefit from further titration under clinical guidance. Our guide to Wegovy mg strengths covers all the approved doses, including this newer addition, in one place.

Who reaches the 2.4 mg stage, and who might not

The licensed eligibility criteria for Wegovy cover adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. None of this means everyone who qualifies will reach 2.4 mg, a prescriber may keep a patient at a lower dose if tolerability is a concern, or if the response at that level is already clinically appropriate.

Wegovy is not recommended during pregnancy, while breastfeeding, or for people trying to conceive. It is not licensed for anyone under 18. A history of certain conditions, including pancreatitis or medullary thyroid carcinoma, requires careful prescriber assessment before starting. These are not edge cases to skim past, they are the kind of individual factors that make a proper clinical consultation the only safe starting point.

The NHS semaglutide medicines page gives a readable overview of who the medicine is and isn't suitable for. If you're weighing up your options more broadly, the weight-loss treatment overview covers the landscape.

Getting the dose right: why this isn't a self-directed process

Some people ask whether they can move to a higher dose faster, stay at a lower one longer, or skip a step. The honest answer is that the titration schedule exists because the clinical evidence supports it, not because it's bureaucratic caution. Rushing upward tends to mean more nausea; staying too low for too long may mean the medicine never reaches its therapeutic range.

A prescriber, not the patient, decides when a dose increase is appropriate. That review considers how the current dose is being tolerated, whether any side effects need addressing, and whether the clinical picture supports moving on. If you've missed doses or had a break in treatment, that conversation becomes even more important before any change is made.

For anyone considering Wegovy through a private route, the starting point is a clinical consultation. At nume, a GPhC-registered Independent Prescriber reads every submission personally (no automated triage) and responds the same day. That review is where dose decisions begin, not the other way round. If that sounds like the right next step, you can start your free consultation and hear from a prescriber directly.